"Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer"@ast . . . . . "10.1038/SREP32946" . . . . . . . . "v\u011Bdeck\u00FD \u010Dl\u00E1nek"@cs . . "Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer."@nl . . . "vedeck\u00FD \u010Dl\u00E1nok"@sk . . "Anja Grah" . "1001459529" . "wetenschappelijk artikel"@nl . . "Johannes Pammer" . "Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer"@ast . "Thorsten Fuereder" . . "wissenschaftlicher Artikel"@de . . . "Marie-Bernadette Aretin" . . "Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer"@en . . . . . . . "Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer"@en . "Hannah Fuchs" . "5011715" . . . "Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer."@nl . . . . . "\u043D\u0430\u0443\u043A\u043E\u0432\u0430 \u0441\u0442\u0430\u0442\u0442\u044F, \u043E\u043F\u0443\u0431\u043B\u0456\u043A\u043E\u0432\u0430\u043D\u0430 \u0443 \u0432\u0435\u0440\u0435\u0441\u043D\u0456 2016"@uk . . . . "\u0645\u0642\u0627\u0644\u0629 \u0639\u0644\u0645\u064A\u0629 \u0646\u0634\u0631\u062A \u0641\u064A 06 \u0633\u0628\u062A\u0645\u0628\u0631 2016"@ar . . . . . . "\u043D\u0430\u0443\u0447\u043D\u0438 \u0447\u043B\u0430\u043D\u0430\u043A"@sr . "27597175" . . . . . . . "32946" . . . . . . "article cient\u00EDfic"@ca . . . "Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer"@en . . . . . . "videnskabelig artikel"@da . "Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer."@nl . . . . . . . . "artigo cient\u00EDfico"@pt . . . . . . . . . "vetenskaplig artikel"@sv . . . . "bilimsel makale"@tr . "articolo scientifico"@it . . . . "article scientifique"@fr . "6" . "Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer"@en . "Doris Posch" . "2016-09-06T00:00:00Z"^^ . . "art\u00EDculu cient\u00EDficu espubliz\u00E1u en 2016"@ast . "Docetaxel plus cetuximab biweekly is an active regimen for the first-line treatment of patients with recurrent/metastatic head and neck cancer"@ast . . . "scientific article published on 06 September 2016"@en . . . .